Supraventricular tachycardia AHA recommendations for Management of Junctional Tachycardia: Difference between revisions
Aysha Aslam (talk | contribs) |
Aysha Aslam (talk | contribs) |
||
Line 22: | Line 22: | ||
| colspan="1" style="text-align:center; background:LemonChiffon"| [[ACC AHA guidelines classification scheme#Classification of Recommendations|Class IIa]] | | colspan="1" style="text-align:center; background:LemonChiffon"| [[ACC AHA guidelines classification scheme#Classification of Recommendations|Class IIa]] | ||
|- | |- | ||
|bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''1.'''Oral beta blockers are reasonable for ongoing management in patients with junctional tachycardia <nowiki>"</nowiki>''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence:C-LD]])'' <nowiki>"</nowiki> | |bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''1.''' Oral beta blockers are reasonable for ongoing management in patients with junctional tachycardia <nowiki>"</nowiki>''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence:C-LD]])'' <nowiki>"</nowiki> | ||
|- | |- | ||
|bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''2.'''Oral diltiazem or verapamil is reasonable for ongoing management in patients with junctional tachycardia <nowiki>"</nowiki>''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence:C-LD]])'' <nowiki>"</nowiki> | |bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''2.''' Oral diltiazem or verapamil is reasonable for ongoing management in patients with junctional tachycardia <nowiki>"</nowiki>''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence:C-LD]])'' <nowiki>"</nowiki> | ||
|} | |} | ||
Line 32: | Line 32: | ||
| colspan="1" style="text-align:center; background:LemonChiffon"| [[ACC AHA guidelines classification scheme#Classification of Recommendations|Class IIb]] | | colspan="1" style="text-align:center; background:LemonChiffon"| [[ACC AHA guidelines classification scheme#Classification of Recommendations|Class IIb]] | ||
|- | |- | ||
|bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''1.'''Flecainide or propafenone may be reasonable for ongoing management in patients without structural heart disease or ischemic heart disease who have junctional tachycardia <nowiki>"</nowiki>''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence:C-LD]])'' <nowiki>"</nowiki> | |bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''1.''' [[Flecainide]] or [[propafenone]] may be reasonable for ongoing management in patients without structural heart disease or ischemic heart disease who have junctional tachycardia <nowiki>"</nowiki>''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence:C-LD]])'' <nowiki>"</nowiki> | ||
|- | |- | ||
|bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''2.'''Catheter ablation may be reasonable in patients with junctional tachycardia when medical therapy is not effective or contraindicated <nowiki>"</nowiki>''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence:C-LD]])'' <nowiki>"</nowiki> | |bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''2.''' [[Catheter ablation]] may be reasonable in patients with junctional tachycardia when medical therapy is not effective or contraindicated <nowiki>"</nowiki>''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence:C-LD]])'' <nowiki>"</nowiki> | ||
|} | |} |
Revision as of 16:43, 27 October 2016
Supraventricular tachycardia Microchapters |
Differentiating Among the Different Types of Supraventricular Tachycardia |
---|
Differentiating Supraventricular Tachycardia from Ventricular Tachycardia |
Diagnosis |
Treatment |
2015 ACC/AHA Guideline Recommendations |
Case Studies |
Supraventricular tachycardia AHA recommendations for Management of Junctional Tachycardia On the Web |
American Roentgen Ray Society Images of Supraventricular tachycardia AHA recommendations for Management of Junctional Tachycardia |
FDA on Supraventricular tachycardia AHA recommendations for Management of Junctional Tachycardia |
CDC on Supraventricular tachycardia AHA recommendations for Management of Junctional Tachycardia |
Blogs on Supraventricular tachycardia AHA recommendations for Management of Junctional Tachycardia |
Directions to Hospitals Treating Supraventricular tachycardia |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Aysha Anwar, M.B.B.S[2]
Overview
Management of Junctional Tachycardia
Acute Treatment of Junctional Tachycardia
Class IIa |
"1. Intravenous beta blockers are reasonable for acute treatment in patients with symptomatic junctional tachycardia "(Level of Evidence:C-LD ) " |
"2. Intravenous diltiazem, procainamide, or verapamil is reasonable for acute treatment in patients with junctional tachycardia "(Level of Evidence:C-LD ) " |
Management of ongoing Junctional Tachycardia
Class IIa |
"1. Oral beta blockers are reasonable for ongoing management in patients with junctional tachycardia "(Level of Evidence:C-LD) " |
"2. Oral diltiazem or verapamil is reasonable for ongoing management in patients with junctional tachycardia "(Level of Evidence:C-LD) " |
Class IIb |
"1. Flecainide or propafenone may be reasonable for ongoing management in patients without structural heart disease or ischemic heart disease who have junctional tachycardia "(Level of Evidence:C-LD) " |
"2. Catheter ablation may be reasonable in patients with junctional tachycardia when medical therapy is not effective or contraindicated "(Level of Evidence:C-LD) " |